Factor IX Polypeptides and Methods of Use Thereof
AssigneeBiogen Hemophilia Inc.
InventorsGlenn PIERCE, Samantha Truex, Robert T. Peters, Haiyan Jiang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
Claims31
1-121. (canceled)
A method of treating hemophilia B in a human subject in need thereof, comprising administering to the subject multiple doses of about 40 IU/kg to about 110 IU/kg of a long-acting Factor IX (“FIX”) polypeptide at a dosing interval of about 7 clays to about 14 clays between two doses, wherein the long-acting FIX polypeptide comprises FIX and an FcRn binding partner (FeRn BP).
Dependencies are inferred from the claim text.